Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Hypoactive Sexual Desire Disorder: Advances in Diagnosis and Treatment

Hypoactive sexual desire disorder, or HSDD, is the most common female sexual dysfunction with about ten percent of premenopausal women in the US be...

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hypoactive sexual desire disorder, or HSDD, is the most common female sexual dysfunction with about ten percent of premenopausal women in the US believed to have this condition. HSDD is consistently under diagnosed, and under managed due to the lack of adequate physician-patient communication on this topic. 

    This CME interview will discuss the symptoms of HSDD, and its impact on a patient’s quality of life along with the components for a comprehensive sexual history. It will also discuss tools for screening and diagnosing HSDD, as well as therapeutic modalities available, and in development, to manage HSDD, including their benefits and potential side effects.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Anita H. Clayton, MD
    David C. Wilson Professor & Chair 
    Department of Psychiatry and Neurobehavioral Sciences
    University of Virginia 
    Charlottesville, VA

    Dr. Clayton receives consulting fees from Fabre-Kramer, Palatin Technologies, S1 Biopharma, Sprout (a division of Valeant Pharmaceuticals), and Takeda and has contracted research for Auspex Pharmaceuticals, Axsome, Forest Research Institute, Inc., Genomind, Inc., Janssen, Palatin Technologies, and Takeda, receives royalties from Ballantine Books/Random House, Changes in Sexual Functioning Questionnaire, and Guilford Publications and has Shares/Restricted Stock Units in Euthymics, and S1 Biopharma.

    Shira Johnson, MD
    Emergency Medicine
    Chicago, IL

    Dr. Johnson has nothing to disclose.


    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Robert Schneider has nothing to disclose.
    • Andrea J. Singer, MD, FACP, CCD serves as a consultant and advisor for Amgen, Eli Lilly, Hologic, Medtronic, Merck, Radius, and UCB and is a speaker for Amgen, Eli Lilly, and Radius.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the symptoms of hypoactive sexual desire disorder.
    • Cite barriers in their clinical practice that inhibit the appropriate diagnosis and management of HSDD.
    • Identify the screening tools that allow for accurate diagnosis of HSDD.
    • Identify the therapeutic modalities currently available, and in development, to manage HSDD including their benefits and potential side effects – also including the first agent approved for this indication (flibanserin).
    • Identify the processes of the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) Program that will allow health care providers/pharmacies to prescribe/dispense flibanserin.
  • Target Audience

    This activity is designed to meet the educational needs of Obstetricians/Gynecologists, Primary Care Physicians, Nurse Practitioners, Physician Assistants, and Certified Nurse Midwives.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Valeant Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.